OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer
Edmond M. Kwan, Chao Dai, Heidi Fettke, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 622-637
Open Access | Times Cited: 28
Edmond M. Kwan, Chao Dai, Heidi Fettke, et al.
JCO Precision Oncology (2021), Iss. 5, pp. 622-637
Open Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Prostate cancer and liquid biopsies: Clinical applications and challenges
Fumihiko Urabe, Takayuki Sumiyoshi, Kojiro Tashiro, et al.
International Journal of Urology (2024) Vol. 31, Iss. 6, pp. 617-626
Open Access | Times Cited: 8
Fumihiko Urabe, Takayuki Sumiyoshi, Kojiro Tashiro, et al.
International Journal of Urology (2024) Vol. 31, Iss. 6, pp. 617-626
Open Access | Times Cited: 8
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Edmond M. Kwan, Lavinia Spain, A. Antón, et al.
European Urology (2021) Vol. 81, Iss. 3, pp. 253-262
Closed Access | Times Cited: 48
Edmond M. Kwan, Lavinia Spain, A. Antón, et al.
European Urology (2021) Vol. 81, Iss. 3, pp. 253-262
Closed Access | Times Cited: 48
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
Heidi Fettke, Chao Dai, Edmond M. Kwan, et al.
EBioMedicine (2023) Vol. 95, pp. 104738-104738
Open Access | Times Cited: 19
Heidi Fettke, Chao Dai, Edmond M. Kwan, et al.
EBioMedicine (2023) Vol. 95, pp. 104738-104738
Open Access | Times Cited: 19
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
Filip Ionescu, Jingsong Zhang, Liang Wang
Cancers (2022) Vol. 14, Iss. 7, pp. 1728-1728
Open Access | Times Cited: 25
Filip Ionescu, Jingsong Zhang, Liang Wang
Cancers (2022) Vol. 14, Iss. 7, pp. 1728-1728
Open Access | Times Cited: 25
BRCA Mutation Testing in Men with Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice
Arun Azad, Howard Gurney, Ainsley Campbell, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Open Access
Arun Azad, Howard Gurney, Ainsley Campbell, et al.
Asia-Pacific Journal of Clinical Oncology (2025)
Open Access
Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors
Kevin Chen, Misty Dawn Shields, Pradeep S. Chauhan, et al.
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 6, pp. 757-774
Open Access | Times Cited: 32
Kevin Chen, Misty Dawn Shields, Pradeep S. Chauhan, et al.
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 6, pp. 757-774
Open Access | Times Cited: 32
Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation
Edmond M. Kwan, Alexander W. Wyatt, Kim N.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 21
Edmond M. Kwan, Alexander W. Wyatt, Kim N.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 21
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Blossom Mak, Hui‐Ming Lin, Edmond M. Kwan, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 17
Blossom Mak, Hui‐Ming Lin, Edmond M. Kwan, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 17
Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients
Hao Liao, Jiayang Zhang, Tiantian Zheng, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Hao Liao, Jiayang Zhang, Tiantian Zheng, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 16
Targeting SphK1/2 by SKI-178 inhibits prostate cancer cell growth
Lü Jin, Jin Zhu, Linya Yao, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 8
Open Access | Times Cited: 10
Lü Jin, Jin Zhu, Linya Yao, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 8
Open Access | Times Cited: 10
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
Harshabad Singh, Kristen E. Lowder, Kevin S. Kapner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Harshabad Singh, Kristen E. Lowder, Kevin S. Kapner, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer
Pradeep S. Chauhan, Irfan Alahi, Savar Sinha, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 151-163
Closed Access | Times Cited: 3
Pradeep S. Chauhan, Irfan Alahi, Savar Sinha, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 151-163
Closed Access | Times Cited: 3
Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
Yifeng Mao, Gaowei Yang, Yingbang Li, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3744-3744
Open Access | Times Cited: 15
Yifeng Mao, Gaowei Yang, Yingbang Li, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3744-3744
Open Access | Times Cited: 15
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS ‐03 trial
Jingyu Zang, Ruiyun Zhang, Di Jin, et al.
The Journal of Pathology (2023) Vol. 261, Iss. 2, pp. 198-209
Closed Access | Times Cited: 8
Jingyu Zang, Ruiyun Zhang, Di Jin, et al.
The Journal of Pathology (2023) Vol. 261, Iss. 2, pp. 198-209
Closed Access | Times Cited: 8
Precision medicine for prostate cancer: An international perspective
Anis Hamid, Christopher J. Sweeney, Christopher M. Hovens, et al.
Urologic Oncology Seminars and Original Investigations (2024) Vol. 42, Iss. 12, pp. 392-401
Closed Access | Times Cited: 2
Anis Hamid, Christopher J. Sweeney, Christopher M. Hovens, et al.
Urologic Oncology Seminars and Original Investigations (2024) Vol. 42, Iss. 12, pp. 392-401
Closed Access | Times Cited: 2
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
Winston Tan, Tiantian Zheng, Amy Wang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Winston Tan, Tiantian Zheng, Amy Wang, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer
Shikai Fang, Shandian Zhe, Hui‐Ming Lin, et al.
JCO Clinical Cancer Informatics (2023), Iss. 7
Open Access | Times Cited: 4
Shikai Fang, Shandian Zhe, Hui‐Ming Lin, et al.
JCO Clinical Cancer Informatics (2023), Iss. 7
Open Access | Times Cited: 4
Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer
Xiaoxi Dong, Tiantian Zheng, Minhua Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 8
Xiaoxi Dong, Tiantian Zheng, Minhua Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 8
Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
Albert Jang, Grant Rauterkus, Ulka N. Vaishampayan, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 897-912
Open Access | Times Cited: 5
Albert Jang, Grant Rauterkus, Ulka N. Vaishampayan, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 897-912
Open Access | Times Cited: 5
Sensitive detection of copy number alterations in samples with low circulating tumor DNA fraction.
Markus Mayrhofer, Rebecka Bergström, Venkatesh Chellappa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Markus Mayrhofer, Rebecka Bergström, Venkatesh Chellappa, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
PIK3/Akt/mTOR pathway alterations in metastatic castration‐sensitive prostate cancer
Philip Sutera, Jongmyung Kim, Ritesh Kumar, et al.
The Prostate (2024) Vol. 84, Iss. 14, pp. 1301-1308
Open Access
Philip Sutera, Jongmyung Kim, Ritesh Kumar, et al.
The Prostate (2024) Vol. 84, Iss. 14, pp. 1301-1308
Open Access
Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival inAR-altered lethal prostate cancer
Pradeep S. Chauhan, Irfan Alahi, Savar Sinha, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Pradeep S. Chauhan, Irfan Alahi, Savar Sinha, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Blood-based liquid biopsy in advanced prostate cancer
Emilio Francesco Giunta, Umberto Malapelle, Antonio Russo, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 194, pp. 104241-104241
Open Access | Times Cited: 1
Emilio Francesco Giunta, Umberto Malapelle, Antonio Russo, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 194, pp. 104241-104241
Open Access | Times Cited: 1
Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer
Louise Kostos, Heidi Fettke, Edmond M. Kwan, et al.
Société Internationale d’Urologie Journal (2023) Vol. 4, Iss. 4, pp. 273-286
Open Access | Times Cited: 1
Louise Kostos, Heidi Fettke, Edmond M. Kwan, et al.
Société Internationale d’Urologie Journal (2023) Vol. 4, Iss. 4, pp. 273-286
Open Access | Times Cited: 1
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
Umang Swami, Raquel M. Zimmerman, Roberto Nussenzveig, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Umang Swami, Raquel M. Zimmerman, Roberto Nussenzveig, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
